Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
View abstract on PubMed
Summary
This summary is machine-generated.Liraglutide significantly reduced cardiovascular events in type 2 diabetes patients. This glucagon-like peptide-1 analogue demonstrated superiority over placebo in preventing major adverse cardiovascular events.
Area Of Science
- Cardiology
- Endocrinology
- Pharmacology
Background
- Cardiovascular disease is a leading cause of mortality in patients with type 2 diabetes.
- The cardiovascular effects of glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide, are of significant clinical interest.
- Previous studies have not fully elucidated the cardiovascular benefits of liraglutide in this high-risk population.
Purpose Of The Study
- To evaluate the cardiovascular safety and efficacy of liraglutide when added to standard care in patients with type 2 diabetes and high cardiovascular risk.
- To determine if liraglutide is noninferior to placebo in reducing the incidence of major adverse cardiovascular events.
Main Methods
- A large-scale, double-blind, randomized controlled trial (LEADER trial) involving 9340 patients with type 2 diabetes and high cardiovascular risk.
- Patients were assigned to receive either liraglutide or placebo, in addition to their standard care.
- The primary composite endpoint was the time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, analyzed using time-to-event methods.
Main Results
- Liraglutide significantly reduced the primary composite outcome compared to placebo (hazard ratio, 0.87; P=0.01 for superiority).
- Cardiovascular death rates were significantly lower in the liraglutide group (4.7% vs. 6.0%; P=0.007).
- All-cause mortality was also significantly reduced with liraglutide (8.2% vs. 9.6%; P=0.02).
Conclusions
- Liraglutide, when added to standard care, significantly reduces the risk of major adverse cardiovascular events and all-cause mortality in patients with type 2 diabetes and high cardiovascular risk.
- The study met its primary hypothesis, demonstrating that liraglutide is not only noninferior but also superior to placebo in reducing cardiovascular events.
- Gastrointestinal events were the most common adverse events leading to discontinuation, while pancreatitis incidence was similar between groups.